PURPOSE: To find associations between knowledge about risk factors for breast cancer and the socioeconomic status of healthy women, as well as their attitude toward taking chemopreventive drugs. PATIENTS AND METHODS: Between April and September 1999, 7135 healthy women completed questionnaires providing information about their willingness to take chemopreventive drugs. Items in the questionnaire included the sources of the information they had, their estimates of the population and personal lifetime risk, and risk factors for breast cancer. RESULTS: A total of 6597 questionnaires were evaluable. The responders' median age was 44. Fifty-five percent of the women were willing to consider receiving chemopreventive drugs to lower their risk for breast cancer. Participants who estimated the population risk as being very high were more disposed to receive chemoprevention (65.3%), as were women who estimated their own breast cancer risk as being high (74.1%). A family history of breast cancer only had a low impact on willingness to receive chemoprevention. Women with a family history of breast cancer were willing to take chemopreventive agents in 57.2% of cases. The multivariate analysis showed that knowing about risk factors and having a lower educational level were factors positively correlated with willingness to consider chemoprevention. CONCLUSION: These findings emphasize the role of estimations of the risk of breast cancer for patients considering whether to accept chemoprevention treatment. To date, only a few modern models of risk estimation have been evaluated in relation to chemoprevention. There is a need for better integration of professional risk estimations into clinical practice.
PURPOSE: To find associations between knowledge about risk factors for breast cancer and the socioeconomic status of healthy women, as well as their attitude toward taking chemopreventive drugs. PATIENTS AND METHODS: Between April and September 1999, 7135 healthy women completed questionnaires providing information about their willingness to take chemopreventive drugs. Items in the questionnaire included the sources of the information they had, their estimates of the population and personal lifetime risk, and risk factors for breast cancer. RESULTS: A total of 6597 questionnaires were evaluable. The responders' median age was 44. Fifty-five percent of the women were willing to consider receiving chemopreventive drugs to lower their risk for breast cancer. Participants who estimated the population risk as being very high were more disposed to receive chemoprevention (65.3%), as were women who estimated their own breast cancer risk as being high (74.1%). A family history of breast cancer only had a low impact on willingness to receive chemoprevention. Women with a family history of breast cancer were willing to take chemopreventive agents in 57.2% of cases. The multivariate analysis showed that knowing about risk factors and having a lower educational level were factors positively correlated with willingness to consider chemoprevention. CONCLUSION: These findings emphasize the role of estimations of the risk of breast cancer for patients considering whether to accept chemoprevention treatment. To date, only a few modern models of risk estimation have been evaluated in relation to chemoprevention. There is a need for better integration of professional risk estimations into clinical practice.
Authors: C Rauh; C C Hack; L Häberle; A Hein; A Engel; M G Schrauder; P A Fasching; S M Jud; A B Ekici; C R Loehberg; M Meier-Meitinger; S Ozan; R Schulz-Wendtland; M Uder; A Hartmann; D L Wachter; M W Beckmann; K Heusinger Journal: Geburtshilfe Frauenheilkd Date: 2012-08 Impact factor: 2.915
Authors: P A Fasching; A B Ekici; B R Adamietz; D L Wachter; A Hein; C M Bayer; L Häberle; C R Loehberg; S M Jud; K Heusinger; M Rübner; C Rauh; M R Bani; M P Lux; R Schulz-Wendtland; A Hartmann; M W Beckmann Journal: Geburtshilfe Frauenheilkd Date: 2011-12 Impact factor: 2.915
Authors: Celine M Vachon; V Shane Pankratz; Christopher G Scott; Lothar Haeberle; Elad Ziv; Matthew R Jensen; Kathleen R Brandt; Dana H Whaley; Janet E Olson; Katharina Heusinger; Carolin C Hack; Sebastian M Jud; Matthias W Beckmann; Ruediger Schulz-Wendtland; Jeffrey A Tice; Aaron D Norman; Julie M Cunningham; Kristen S Purrington; Douglas F Easton; Thomas A Sellers; Karla Kerlikowske; Peter A Fasching; Fergus J Couch Journal: J Natl Cancer Inst Date: 2015-03-04 Impact factor: 13.506
Authors: Michael P Lux; Julius Emons; Mayada R Bani; Marius Wunderle; Charlotte Sell; Caroline Preuss; Claudia Rauh; Sebastian M Jud; Felix Heindl; Hanna Langemann; Thomas Geyer; Anna-Lisa Brandl; Carolin C Hack; Werner Adler; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Peter A Fasching; Paul Gass Journal: Breast Care (Basel) Date: 2019-01-30 Impact factor: 2.860
Authors: Lothar Häberle; Florian Wagner; Peter A Fasching; Sebastian M Jud; Katharina Heusinger; Christian R Loehberg; Alexander Hein; Christian M Bayer; Carolin C Hack; Michael P Lux; Katja Binder; Matthias Elter; Christian Münzenmayer; Rüdiger Schulz-Wendtland; Martina Meier-Meitinger; Boris R Adamietz; Michael Uder; Matthias W Beckmann; Thomas Wittenberg Journal: Breast Cancer Res Date: 2012-04-10 Impact factor: 6.466
Authors: U G Poehls; C C Hack; A B Ekici; M W Beckmann; P A Fasching; M Ruebner; H Huebner Journal: Eur J Med Res Date: 2018-04-27 Impact factor: 2.175
Authors: Jenna Matin; Rachel McFarland Lucia; Krustina Lal; Alyssa Columbus; Deborah Goodman; Kathryn Larsen; Argyrios Ziogas; Hannah Lui Park Journal: J Prim Care Community Health Date: 2021 Jan-Dec